Dalcetrapib: no off-target toxicity on blood pressure or on genes related to the renin-angiotensin-aldosterone system in rats.

British Journal of Pharmacology
Erik S G StroesEric J Niesor

Abstract

The association between torcetrapib and its off-target effects on blood pressure suggested a possible class-specific effect. The effects of dalcetrapib (RO4607381/JTT-705) and torcetrapib on haemodynamics and the renin-angiotensin-aldosterone system (RAAS) were therefore assessed in a rat model. Arterial pressure (AP) and heart rate were measured by telemetry in normotensive and spontaneously hypertensive rats (SHR) receiving torcetrapib 10, 40 or 80 mg kg(-1) day(-1); dalcetrapib 100, 300 or 500 mg(-1) kg day(-1); or vehicle (placebo) for 5 days. Expression of RAAS genes in adrenal gland, kidney, aorta and lung from normotensive rats following 5 days' treatment with torcetrapib 40 mg kg(-1) day(-1), dalcetrapib 500 mg kg(-1) day(-1) or vehicle was measured by quantitative polymerase chain reaction. Torcetrapib transiently increased mean AP in normotensive rats (+3.7 +/- 0.1 mmHg), whereas treatment in SHR resulted in a dose-dependent and sustained increase [+6.5 +/- 0.6 mmHg with 40 mg kg(-1) day(-1) at day 1 (P < 0.05 versus placebo)], which lasted over the treatment period. No changes in AP or heart rate were observed with dalcetrapib. Torcetrapib, but not dalcetrapib, increased RAAS-related mRNAs in adrenal glands and aorta...Continue Reading

References

Aug 13, 2002·Arteriosclerosis, Thrombosis, and Vascular Biology·Allan R BrasierMohsen S Eledrisi
Feb 18, 2003·Arteriosclerosis, Thrombosis, and Vascular Biology·Philip J BarterAlan R Tall
Jan 24, 2004·Arteriosclerosis, Thrombosis, and Vascular Biology·Ronald W ClarkMark J Bamberger
Mar 29, 2005·American Journal of Physiology. Heart and Circulatory Physiology·Maria A PotenzaMonica Montagnani
Apr 22, 2005·The American Journal of Cardiology·Jan Albert KuivenhovenJohn J P Kastelein
Sep 1, 2005·The Journal of Laboratory and Clinical Medicine·Lilach O LermanClaudio Napoli
Feb 7, 2006·Journal of the American College of Cardiology·Philip J Barter, John J P Kastelein
Jan 24, 2007·Nature Structural & Molecular Biology·Xiayang QiuAndrew P Seddon
Mar 28, 2007·The New England Journal of Medicine·Steven E NissenUNKNOWN ILLUSTRATE Investigators
Mar 28, 2007·The New England Journal of Medicine·John J P KasteleinUNKNOWN RADIANCE 1 Investigators
Nov 7, 2007·The New England Journal of Medicine·Philip J BarterUNKNOWN ILLUMINATE Investigators
Dec 11, 2007·Lancet·Patrick Duriez
May 2, 2008·British Journal of Pharmacology·S P H AlexanderJ A Peters
Jul 7, 2009·The American Journal of Cardiology·Evan A SteinJohn J P Kastelein

❮ Previous
Next ❯

Citations

Jan 23, 2010·Cardiovascular Drugs and Therapy·Robert S Rosenson
Jun 2, 2012·Journal of Medicinal Chemistry·Lalgudi S HarikrishnanR Michael Lawrence
Sep 27, 2012·Current Opinion in Lipidology·Raphaël Duivenvoorden, Zahi A Fayad
Oct 12, 2011·Lipids in Health and Disease·Santiago RedondoTeresa Tejerina
May 3, 2012·Journal of Lipid Research·Philip J Barter, Kerry-Anne Rye
Oct 12, 2012·Drug Design, Development and Therapy·Alyse S Goldberg, Robert A Hegele
Jun 4, 2014·Current Atherosclerosis Reports·Angela PirilloAlberico Luigi Catapano
Feb 15, 2012·Expert Opinion on Investigational Drugs·Sheila A Doggrell
May 15, 2010·Expert Opinion on Investigational Drugs·Jennifer G Robinson
Jun 26, 2012·Expert Opinion on Investigational Drugs·Amanda J Hooper, John R Burnett
Apr 3, 2012·Pharmacology & Therapeutics·Tisha R Joy
Nov 15, 2011·Atherosclerosis·Jane Stock
Sep 13, 2011·Lancet·Erik S G Stroes, Diederik F van Wijk
Apr 21, 2017·Current Opinion in Lipidology·Roelof Aj SmitStella Trompet
May 16, 2013·Circulation. Cardiovascular Quality and Outcomes·Ioannis KaralisJ Wouter Jukema
Mar 13, 2010·Expert Review of Cardiovascular Therapy·Khalid AlwailiJacques Genest
Dec 2, 2011·Clinical Pharmacology and Therapeutics·D E GutsteinJ A Wagner
Mar 9, 2013·Expert Review of Cardiovascular Therapy·Steven Campbell, Jacques Genest
May 8, 2018·Clinical Pharmacokinetics·Donald M BlackTherese Heinonen

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.